Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cardiology, Ocular |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Ophthalmology |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 11/10/2018 |
| Start Date: | March 26, 2018 |
| End Date: | June 2019 |
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and effects of repeated intravitreal
injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with
aflibercept in patients with wet macular degeneration.
injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with
aflibercept in patients with wet macular degeneration.
Inclusion Criteria:
- Males or females of any race, ≥50 years of age
- Active primary CNV secondary to AMD in the study eye
Exclusion Criteria:
- Any prior treatment of CNV or advanced AMD in the study eye, except for dietary
supplements or vitamins
- Any intraocular or ocular surface surgery (including cataract surgery and laser
procedures) in the study eye within 3 months
- Vitrectomy in the study eye
We found this trial at
8
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials